Silent Cancers Predominant in the United States; Lung and Breast Cancer Cases on the Rise

Share Article

According to the new report from BCC Research, the global market for “silent” cancers was valued at $8.5 billion in 2013 and $9 billion in 2014. This market is expected to reach almost $13.6 billion by 2019, with a compound annual growth rate (CAGR) of 8.5% from 2014 to 2019.

Silent Cancers
The global market for “silent” cancers is expected to reach almost $13.6 billion by 2019.

BCC Research ( reveals in its new report on “silent” cancers that while oncology spending remains concentrated among the United States (U.S.) and the five largest European countries, the rising prevalence of cancer and greater patient access to treatments in emerging nations has propelled oncology to the fifth-largest therapy area in those markets.

According to experts, the number of global cancer cases is projected to rise by 75% in 2030, as the Western way of life, which sadly has been linked to cancer, is being adopted by many across the world. Cancers that are caused by infections, such as cervical cancer and some liver and stomach cancers, are currently under control and have decreasing incidence rates. However, experts feel that cancers of the lung, colon, and breast are rising in number.

Among the total spectrum of malignant diseases there is a group of cancers, which, although affecting smaller patient populations than the “big four,” are more devastating. These are the “silent cancers” which give little indication of their growth until an advanced stage, at which time prospects of successful treatment are much reduced and the prognosis is poor. These comprise of cervical cancer, ovarian cancer, brain cancer, oropharyngeal cancer, esophageal cancer, liver cancer, pancreatic cancer, and kidney cancer.

“Targeted therapies have dramatically increased their share of global oncology sales, from 11% a decade ago to 46% last year,” says BCC Research analyst Paul Evers. “Payers have intensified their scrutiny of the value of these medicines relative to their incremental benefits over existing treatments. At the same time, the average cost per month for a branded oncology drug in the U.S. is now approximately $10,000, up from an average of $5,000 a decade ago.”

Concentrated or single-payer health systems, and those utilizing health technology assessments to evaluate the value of treatments, tend to pay less than U.S. prices for medicines. The pricing discount mechanisms used in major European markets typically drive net prices down by approximately 20% to 40% compared with U.S. list prices.

Therapeutics for 'Silent' Cancers provides detailed market, technology, and industry analyses to help readers quantify and qualify the market for eight subtypes of cancer. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2019.

Editors and reporters who wish to speak with the analyst should contact Steven Cumming at

About BCC Research
BCC Research publishes market research reports that make organizations worldwide more profitable with intelligence that drives smart business decisions. These reports cover today's major industrial and technology sectors, including emerging markets. For more than 40 years we've helped customers identify new market opportunities with accurate and reliable data and insight, including market sizing, forecasting, industry overviews, and identification of significant trends and key market participants. We partner with analysts who are experts in specific areas of industry and technology, providing unbiased measurements and assessments of global markets. Recently selected as the world’s greatest market research company, BCC Research is a unit of Eli Global, LLC. Visit our website at Contact us: (+1) 781-489-7301 (U.S. Eastern Time), or email

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Steven Cumming
BCC Research
+1 (781) 489-7301 Ext: 632
Email >
Follow >
Visit website